An altered treatment plan based on direct to consumer (DTC) genetic testing: Personalized medicine from the patient/pin-cushion perspective

Journal of Personalized Medicine

Volumn 2, Issue 4, 2012, Pages 192-200

  Tenenbaum, Jessica D ^a   James, Andra ^b   Paulyson Nuñez, Kristin ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Clotting disorders; Direct to consumer genetic testing; Genetic counseling; Personalized medicine; Pregnancy; Thrombophilia; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; PROTHROMBIN;

ARTICLE; CASE REPORT; DELIVERY; DRUG DOSE REDUCTION; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HETEROZYGOSITY; HUMAN; PATIENT ATTITUDE; PERSONALIZED MEDICINE; PREGNANCY; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

EID: 85011593795     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm2040192     Document Type: Article

References (25)

1. Hood, L.; Friend, S.H. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 2011, 8, 184-187.
2. Hood, L.; Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory. New Biotechnol. 2012, 29, 613-624.
3. Tian, Q.; Price, N.D.; Hood, L. Systems cancer medicine: Towards realization of predictive, preventive, personalized and participatory (P4) medicine. J. Intern. Med. 2012, 271, 111-121.
4. Auffray, C.; Charron, D.; Hood, L. Predictive, preventive, personalized and participatory medicine: Back to the future. Genome Med. 2010, 2, doi:10.1186/gm178.
5. Harmon, K. Genome Sequencing for the Rest of Us. Scientific American 2010. Available online: http://www.scientificamerican.com/article.cfm?id=personal-genome-sequencing (accessed on 24 August 2012).
6. Guttmacher, A.E.; Collins, F.S. Genomic medicine-A primer. N. Engl. J. Med. 2002, 347, 1512-1520.
7. Trusheim, M.R.; Berndt, E.R.; Douglas, F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6, 287-293.
8. National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Available online: http://www.ucsf.edu/sites/default/files/documents/new-taxonomy.pdf (accessed on 24 August 2012).
9. Evans, W.E.; Relling, M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429, 464-468.
10. Manolio, T.A.; Collins, F.S.; Cox, N.J.; Goldstein, D.B.; Hindorff, L.A.; Hunter, D.J.; McCarthy, M.I.; Ramos, E.M.; Cardon, L.R.; Chakravarti, A.; et al. Finding the missing heritability of complex diseases. Nature 2009, 461, 747-753.
11. Burke, W.; Psaty, B.M. Personalized medicine in the era of genomics. JAMA 2007, 298, 1682-1684.
12. Wu, S. 23andMe Inc., Mountain View, CA, USA. Personal Communication, 25 June 2012 13.
13. Franco, R.F.; Santos, S.E.; Elion, J.; Tavella, M.H.; Zago, M.A. Prevalence of the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in different human populations. Acta Haematol. 1998, 100, 9-12.
14. Pihusch, R.; Buchholz, T.; Lohse, P.; Rubsamen, H.; Rogenhofer, N.; Hasbargen, U.; Hiller, E.; Thaler, C.J. Thrombophilic gene mutations and recurrent spontaneous abortion: Prothrombin mutation increases the risk in the first trimester. Am. J. Reprod. Immunol. 2001, 46, 124-131.
15. Alfirevic, Z.; Roberts, D.; Martlew, V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002, 101, 6-14.
16. Wu, O.; Robertson, L.; Twaddle, S.; Lowe, G.D.; Clark, P.; Greaves, M.; Walker, I.D.; Langhorne, P.; Brenkel, I.; Regan, L.; et al. Screening for thrombophilia in high-risk situations: Systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess. 2006, 10, 1-110.
17. Silver, R.M.; Zhao, Y.; Spong, C.Y.; Sibai, B.; Wendel, G., Jr.; Wenstrom, K.; Samuels, P.; Caritis, S.N.; Sorokin, Y.; Miodovnik, M.; et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet. Gynecol. 2010, 115, 14-20.
18. Jacobsen, A.F.; Dahm, A.; Bergrem, A.; Jacobsen, E.M.; Sandset, P.M. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J. Thromb Haemost. 2010, 8, 2443-2449.
19. Peters, E.; Hibbard, J.; Slovic, P.; Dieckmann, N. Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Aff. (Millwood) 2007, 26, 741-748.
20. James, A.H.; Jamison, M.G.; Brancazio, L.R.; Myers, E.R. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. Am. J. Obstet. Gynecol. 2006, 194, 1311-1315.
21. EGAPP Working Group. Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet. Med. 2011, 13, 67-76.
22. Spector, E.B.; Grody, W.W.; Matteson, C.J.; Palomaki, G.E.; Bellissimo, D.B.; Wolff, D.J.; Bradley, L.A.; Prior, T.W.; Feldman, G.; Popovich, B.W.; et al. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G>A testing): A disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet. Med. 2005, 7, 444-453.
23. Lockwood, C.; Wendel, G. Practice bulletin No. 124: Inherited thrombophilias in pregnancy. Obstet. Gynecol. 2011, 118, 730-770.
24. Stead, W.W.; Searle, J.R.; Fessler, H.E.; Smith, J.W.; Shortliffe, E.H. Biomedical informatics: Changing what physicians need to know and how they learn. Acad. Med. 2011, 86, 429-434.
25. McGinnis, J.M. Evidence-based medicine-Engineering the Learning Healthcare System. Stud. Health Technol. Inform. 2010, 153, 145-157.